Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab
| Autor: | Rena Buckstein, Nancy Pennell, David Spaner, Karen Hewitt, Kevin Rimrie, Neil L. Berinstein |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.drug_class Follicular lymphoma Antineoplastic Agents Monoclonal antibody Gastroenterology Polymerase Chain Reaction Translocation Genetic Antibodies Monoclonal Murine-Derived Refractory immune system diseases Recurrence hemic and lymphatic diseases Internal medicine Follicular phase Medicine Humans Lymphoma Follicular Chromosomes Human Pair 14 business.industry Remission Induction Antibodies Monoclonal Hematology medicine.disease Peripheral blood Lymphoma Oncology Immunology Rituximab business Chromosomes Human Pair 18 After treatment medicine.drug Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 41(3-4) |
| ISSN: | 1042-8194 |
| Popis: | Rituximab is a chimeric anti-CD20 monoclonal antibody that has approval for single agent therapy in the treatment of relapsed/refractory low grade or follicular non-Hodgkin's Lymphoma. In published phase II trials, molecular remissions of PCR detectable t(14; 18) disease in the peripheral blood have been reported in up to 62% of patients by three months. We report a case of a patient who achieved prolonged clinical and molecular remission following a single four week course of Rituximab that has exceeded any previous remission achieved with cheino-radiotherapy. The implications of molecular remission as a surrogate of clinical remission and molecular relapse as a harbinger of clinical relapse are reviewed and discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |